Lowest-Rated StocksLowest-RatedNASDAQ:SAGE Sage Therapeutics (SAGE) Stock Price, News & Analysis $10.99 +0.52 (+4.97%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$10.49▼$11.0050-Day Range$10.38▼$13.0852-Week Range$9.73▼$37.17Volume926,659 shsAverage Volume1.11 million shsMarket Capitalization$661.38 millionP/E RatioN/ADividend YieldN/APrice Target$33.55 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Sage Therapeutics alerts: Email Address Sage Therapeutics MarketRank™ Stock AnalysisAnalyst RatingHold2.00 Rating ScoreUpside/Downside205.3% Upside$33.55 Price TargetShort InterestBearish11.25% of Float Sold ShortDividend StrengthN/ASustainability-1.64Upright™ Environmental ScoreNews Sentiment-0.08Based on 39 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($6.54) to ($5.01) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.32 out of 5 starsMedical Sector169th out of 936 stocksPharmaceutical Preparations Industry71st out of 436 stocks 4.0 Analyst's Opinion Consensus RatingSage Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 2 buy ratings, 16 hold ratings, and 2 sell ratings.Amount of Analyst CoverageSage Therapeutics has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Sage Therapeutics' stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted11.25% of the float of Sage Therapeutics has been sold short.Short Interest Ratio / Days to CoverSage Therapeutics has a short interest ratio ("days to cover") of 4.5.Change versus previous monthShort interest in Sage Therapeutics has recently decreased by 1.76%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldSage Therapeutics does not currently pay a dividend.Dividend GrowthSage Therapeutics does not have a long track record of dividend growth. Previous Next 4.2 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreSage Therapeutics has received a 61.41% net impact score from Upright. The largest positive contribution comes from its "Mental diseases" impact, which is driven by its "Antidepressants" and "Clinical research services for mental health" products. See details.Environmental SustainabilityThe Environmental Impact score for Sage Therapeutics is -1.64. Previous Next 1.6 News and Social Media Coverage News SentimentSage Therapeutics has a news sentiment score of -0.08. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 39 news articles for Sage Therapeutics this week, compared to 5 articles on an average week.Search InterestOnly 1 people have searched for SAGE on MarketBeat in the last 30 days. This is a decrease of -90% compared to the previous 30 days.MarketBeat Follows2 people have added Sage Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Sage Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.50% of the stock of Sage Therapeutics is held by insiders.Percentage Held by Institutions99.22% of the stock of Sage Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Sage Therapeutics' insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Sage Therapeutics are expected to grow in the coming year, from ($6.54) to ($5.01) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Sage Therapeutics is -1.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Sage Therapeutics is -1.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSage Therapeutics has a P/B Ratio of 0.83. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Sage Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here About Sage Therapeutics Stock (NASDAQ:SAGE)Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression. Its product pipeline also comprises SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases; and SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which is in Phase II clinical trial for the treatment of depression, Huntington's disease, Parkinson's diseases, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. The company has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.Read More SAGE Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SAGE Stock News HeadlinesJuly 26 at 12:36 PM | globenewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sage Therapeutics, Inc. - SAGEJuly 26 at 10:12 AM | americanbankingnews.comSage Therapeutics (NASDAQ:SAGE) Cut to "Neutral" at JPMorgan Chase & Co.July 27, 2024 | Stansberry Research (Ad)Get out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all $20,000 of his wife's 401k into shares of just ONE stock. Everyone on Wall Street said he was crazy. But a year later, that $20,000 in his wife's account was worth $120,000. Today, he says: "If you thought the dot-com mania was intense, what's about to happen in the coming weeks could be even crazier and could open up a new window of opportunity for 500%-plus gains."July 26 at 7:20 AM | americanbankingnews.comSage Therapeutics (NASDAQ:SAGE) Given Neutral Rating at HC WainwrightJuly 26 at 4:18 AM | markets.businessinsider.comSAGE Therapeutics: Hold Rating Following SAGE-324 Clinical Trial SetbackJuly 26 at 1:53 AM | americanbankingnews.comSage Therapeutics (NASDAQ:SAGE) Reaches New 12-Month Low After Analyst DowngradeJuly 25 at 6:15 PM | seekingalpha.comSage Therapeutics: Tremors Of Trouble, But PPD Progress (Rating Downgrade)July 25 at 1:59 PM | globenewswire.comSage Therapeutics, Inc. (SAGE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged WrongdoingsJuly 27, 2024 | Stansberry Research (Ad)Get out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all $20,000 of his wife's 401k into shares of just ONE stock. Everyone on Wall Street said he was crazy. But a year later, that $20,000 in his wife's account was worth $120,000. Today, he says: "If you thought the dot-com mania was intense, what's about to happen in the coming weeks could be even crazier and could open up a new window of opportunity for 500%-plus gains."July 25 at 1:15 PM | msn.comBiotech Stock Roundup: SAGE Plunges on Study Failure, AGEN Down on Regulatory Update & MoreJuly 25 at 1:15 PM | msn.comSage Therapeutics cut to Neutral at J.P. Morgan on pipeline concernsJuly 25 at 8:28 AM | americanbankingnews.comSage Therapeutics (NASDAQ:SAGE) Price Target Cut to $13.00 by Analysts at Robert W. BairdJuly 25 at 8:12 AM | marketwatch.comSage Therapeutics Shares Tumble Premarket on Essential Tremor Study FailureJuly 24 at 11:14 PM | benzinga.comSage, Biogen Shelve Development Of Nervous System Disorder Drug After Data DisappointsJuly 24 at 9:45 PM | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sage Therapeutics, Inc. - SAGEJuly 24 at 10:34 AM | barrons.comSage Therapeutics Stock Slides as Pipeline ThinsJuly 24 at 10:17 AM | americanbankingnews.comNeedham & Company LLC Reiterates "Hold" Rating for Sage Therapeutics (NASDAQ:SAGE)July 24 at 8:55 AM | americanbankingnews.comAnalysts Set Sage Therapeutics, Inc. (NASDAQ:SAGE) Target Price at $34.45See More Headlines Receive SAGE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sage Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings4/25/2024Today7/26/2024Next Earnings (Confirmed)7/31/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:SAGE CUSIPN/A CIK1597553 Webwww.sagerx.com Phone(617) 299-8380Fax617-299-8379Employees487Year FoundedN/APrice Target and Rating Average Stock Price Target$33.55 High Stock Price Target$294.00 Low Stock Price Target$8.00 Potential Upside/Downside+208.9%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage20 Analysts Profitability EPS (Most Recent Fiscal Year)($8.40) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-541,490,000.00 Net Margins-552.52% Pretax Margin-552.52% Return on Equity-56.81% Return on Assets-51.01% Debt Debt-to-Equity RatioN/A Current Ratio12.22 Quick Ratio12.22 Sales & Book Value Annual Sales$86.46 million Price / Sales7.65 Cash FlowN/A Price / Cash FlowN/A Book Value$13.32 per share Price / Book0.83Miscellaneous Outstanding Shares60,180,000Free Float56,872,000Market Cap$661.38 million OptionableOptionable Beta0.90 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesMr. Barry E. Greene (Age 61)President, CEO & Director Comp: $1.29MMs. Kimi E. Iguchi CPA (Age 62)CFO & Treasurer Comp: $665.37kMs. Anne Marie Cook Esq. (Age 62)Senior VP, General Counsel & Secretary Comp: $711.6kMr. Christopher Benecchi (Age 52)Chief Business Officer Comp: $703.76kDr. Laura Gault M.D.Ph.D., Chief Medical OfficerMr. Matt LasmanisChief Technology & Innovation OfficerMr. Mike QuirkChief Scientific OfficerAshley KaplowitzDirector of Investor RelationsMs. Erin E. Lanciani (Age 55)Chief People & Experience Officer Dr. Amy Schacterle Ph.D.Senior Vice President of R&D Strategy and Business ManagementMore ExecutivesKey CompetitorsEmergent BioSolutionsNYSE:EBSAmicus TherapeuticsNASDAQ:FOLDRhythm PharmaceuticalsNASDAQ:RYTMACADIA PharmaceuticalsNASDAQ:ACADMoonLake ImmunotherapeuticsNASDAQ:MLTXView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 37,691 shares on 7/26/2024Ownership: 0.363%Easterly Investment Partners LLCBought 27,000 shares on 7/25/2024Ownership: 0.227%Baillie Gifford & Co.Sold 17,483 shares on 7/25/2024Ownership: 0.105%Hennion & Walsh Asset Management Inc.Sold 24,730 shares on 7/20/2024Ownership: 0.070%Nisa Investment Advisors LLCSold 12,885 shares on 7/20/2024Ownership: 0.010%View All Insider TransactionsView All Institutional Transactions SAGE Stock Analysis - Frequently Asked Questions How have SAGE shares performed this year? Sage Therapeutics' stock was trading at $21.67 at the beginning of 2024. Since then, SAGE shares have decreased by 49.3% and is now trading at $10.99. View the best growth stocks for 2024 here. How were Sage Therapeutics' earnings last quarter? Sage Therapeutics, Inc. (NASDAQ:SAGE) posted its quarterly earnings data on Thursday, April, 25th. The biopharmaceutical company reported ($1.80) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.63) by $0.17. The company's revenue was up 139.4% on a year-over-year basis. Who are Sage Therapeutics' major shareholders? Top institutional investors of Sage Therapeutics include Bank of New York Mellon Corp (0.36%), Assenagon Asset Management S.A. (0.28%), Easterly Investment Partners LLC (0.23%) and Baillie Gifford & Co. (0.11%). Insiders that own company stock include Barry E Greene, George Golumbeski and Elizabeth Barrett. View institutional ownership trends. How do I buy shares of Sage Therapeutics? Shares of SAGE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Sage Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Sage Therapeutics investors own include NVIDIA (NVDA), AbbVie (ABBV), Micron Technology (MU), Alibaba Group (BABA), Advanced Micro Devices (AMD), Gilead Sciences (GILD) and Netflix (NFLX). This page (NASDAQ:SAGE) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | Sponsoredtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredThe #1 Crypto for 2024 (3 Cent Coin)Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredAlex's "Next Magnificent Seven" StocksToday Alex Green is releasing his new breakdown of AI's "Next Magnificent Seven." So please make some time ...The Oxford Club | SponsoredNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands o...Monument Traders Alliance | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sage Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sage Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SAGE Stock Alerts